Moderna Inc. (MRNA) - Q4 2025 (USD): Revenue 678mln (exp. 635mln), EPS -2.11 (exp. -2.54)

Moderna's Q4 2025 results show a revenue beat against expectations, which indicates stronger operational performance and could positively influence investor sentiment.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Ukraine President Zelensky says Ukraine plans to open 10 joint drone production facilities this year; he visited joint Ukrainian-German drone production

Moderna Inc. (MRNA) Q4 2025 (USD): EPS -2.11 (exp. -2.54), Revenue 700mln (exp. 635mln)

Moderna Inc. (MRNA) - Q4 2025 (USD): Revenue 678mln (exp. 635mln), EPS -2.11 (exp. -2.54)

Russia's Foreign Minister Lavrov held a phone call with his Saudi counterpart, TASS reports; talks were focused on Iran and Gaza

OPEC+ has reportedly not decided on output plans for April as it stands, Bloomberg reports citing sources; some see scope to resume supply hikes in April

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

The narrower EPS loss compared to expectations also suggests improved cost management or higher efficiency; however, the ongoing losses may still raise concerns regarding profitability moving forward. Overall, these results could bolster confidence in the biotechnology sector, but caution is warranted given the continued losses, affecting how the stock might react in conjunction with broader market conditions.

Related headlines

The whole workspace, free to try.

Try it free